Depression + metabolic risk factors boost chances of Type 2 diabetes Adding a DPP-4 inhibitor to sulfonylurea therapy increases hypoglycemia risk by 50%Sulfonylurea dose should be reduced when starting a DPP-4 inhibitor in type 2 diabetes. Updated Canadian diabetes guidelines for pharmacologic management of type 2 diabetes Empagliflozin should be added when glycemic targets are not met in patients with clinical cardiovascular disease. CE Lesson: Type 2 Diabetes Individualizing drug therapy in T2D. Getting the real scoop on sugar Reversing diabetes for good? VIDEO: The effects of diabetes on erectile dysfunction Ask the Diabetes Expert: Managing lifestyle choices VIDEO: Gender-specific issues in diabetes A diabetes network for pharmacists First Previous 39 40 41 42 43 Next Last
